邮寄自采样HPV检测套件提高安全网医疗系统宫颈癌筛查参与度:混合效果-实施随机对照试验方案
PRESTIS试验是一项混合2型效果-实施务实随机对照试验,旨在评估邮寄自采样HPV检测套件在安全网医疗系统中对宫颈癌筛查参与度的效果,同时评估患者导航作为实施策略的作用。试验计划招募2268名参与者,随机分为三组:电话召回组、电话召回加邮寄自采样HPV检测套件组、电话召回加邮寄套件加患者导航组。主要效果结局是完成初筛(返回自采样套件或完成临床Pap涂片)。
要点
- 邮寄自采样HPV检测套件可能提高未及时筛查女性的宫颈癌筛查参与度。
- 患者导航作为实施策略可能进一步改善自采样筛查项目的成功率。
- 该试验在服务少数族裔为主的安全网医疗系统中进行,针对医疗服务不足人群。
核心结论
- 该试验旨在评估邮寄自采样HPV检测套件在安全网医疗系统中提高宫颈癌筛查参与度的效果,并评估患者导航实施策略。
研究设计与样本
- PRESTIS试验为混合2型效果-实施务实随机对照试验,计划招募2268名参与者。
- 参与者随机分为三组:电话召回组(n=756)、电话召回加邮寄自采样HPV检测套件组(n=756)、电话召回加邮寄套件加患者导航组(n=756)。
- 研究在大型城市安全网医疗系统中进行,服务以少数族裔为主的患者人群。
关键数值与推荐
- 主要效果结局为完成初筛,定义为完成并返回邮寄自采样套件或完成临床Pap涂片。
- 次要效果结局包括筛查预测因素和筛查阳性女性的临床随访参与率。
- 实施结局包括覆盖范围、可接受性、保真度、 adaptations和成本效果。
临床怎么用
- 邮寄自采样HPV检测套件可能作为提高宫颈癌筛查参与度的策略,尤其适用于未及时进行临床筛查的人群。
- 患者导航可作为实施策略,帮助解决患者层面的参与障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Almost 20% of U.S. women remain at risk for cervical cancer due to their inability or unwillingness to participate in periodic clinic-based screening. Self-sampling has been shown to be an effective strategy for screening women for high-risk human papillomavirus (HR-HPV) infection in specific contexts. However, its effectiveness among medically underserved women in safety net health systems has not been evaluated. Furthermore, it is also unclear whether implementation strategies such as patient navigation can be used to improve the success of self-sample screening programs by addressing patient-level barriers to participation. METHODS/DESIGN: The Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) trial is a hybrid type 2 effectiveness-implementation pragmatic randomized controlled trial of mailed self-sample HPV testing. The aim is to assess the effectiveness of mailed self-sample HPV testing kits to improve cervical cancer screening participation among patients in a safety net health system who are overdue for clinic-based screening, while simultaneously assessing patient navigation as an implementation strategy. Its setting is a large, urban safety net health system that serves a predominantly racial/ethnic minority patient population. The trial targets recruitment of 2268 participants randomized to telephone recall (enhanced usual care, n = 756), telephone recall with mailed self-sample HPV testing kit (intervention, n = 756), or telephone recall with mailed self-sample HPV testing kit and patient navigation (intervention + implementation strategy, n = 756). The primary effectiveness outcome is completion of primary screening, defined as completion and return of mailed self-sample kit or completion of a clinic-based Pap test. Secondary effectiveness outcomes are predictors of screening and attendance for clinical follow-up among women with a positive screening test. Implementation outcomes are reach, acceptability, fidelity, adaptations, and cost-effectiveness. DISCUSSION: Hybrid designs are needed to evaluate the clinical effectiveness of self-sample HPV testing in specific populations and settings, while incorporating and evaluating methods to optimize its real-world implementation. The current manuscript describes the rationale and design of a hybrid type 2 trial of self-sample HPV testing in a safety net health system. Trial findings are expected to provide meaningful data to inform screening strategies to ultimately realize the global goal of eliminating cervical cancer. TRIAL REGISTRATION: ClinicalTrials.gov NCT03898167 . Registered on 01 April 2019. TRIAL STATUS: Study start data: February 13, 2020. Recruitment status: Enrolling by invitation. Estimated primary completion date: February 15, 2023. Estimated study completion date: May 31, 2024. Protocol version 1.6 (February 25, 2020).
引用
- Montealegre JR, Anderson ML, Hilsenbeck SG, et al. Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial. Trials. 2020. PMID: 33087164. doi:10.1186/s13063-020-04790-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。